


#4887
9-1-02

PATENTS w/attach

Attorney Docket No. 25352-0022



CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the US Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington DC 20231, on July 23, 2002.

Derek P. Freyberg
Derek P. Freyberg, Reg. No. 29,250

7/23/02
Date

RECEIVED
JUL 31 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hugo O. Villar, et al. : Confirmation No.: 2049

App. No.: 10/082,801 : Art Unit: 1645

Filed: February 22, 2002 : Examiner: Not yet Known

For: ACRIDINES AS STIMULATORS FOR FAS-MEDIATED APOPTOSIS

Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT


Applicant directs the attention of the Office to the documents listed on the attached Form PTO-1449 substitute (1 sheet), which may be relevant to the examination of this application.

This application claims the benefit under 35 USC 119(e) of Application No. 60/274,535, filed March 8, 2001.

The Examiner is requested to initial and return a copy of each of these forms with future communications relating to this application.

No representation is made by this Information Disclosure Statement that a search has been made; or that the information disclosed is, or is considered to be, material to patentability under 37 CFR 1.56(b).

Respectfully submitted,



Derek P. Freyberg
Attorney for Applicant
Reg. No. 29,250

Customer No.: 25213

Heller Ehrman White & McAuliffe
275 Middlefield Road
Menlo Park, California 94025-3506
(650) 324-7014
July 23, 2002

370140 v01.SV (7x1_01!.DOC)
07/23/02 2:51 PM0

RECEIVED
JUL 31 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT (37 CFR 1.56, 1.97, and 1.98) SHEET 1 OF 1				ATTORNEY DOCKET	APPLICATION NO.	
				25352-0022	10/082,801	
				APPLICANT(S)		
				Hugo O. Villar, et al.		
FILING DATE			GROUP			
February 8, 2002			1645			
U.S. PATENT DOCUMENTS						
† EX'R INITIAL	*	REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS
	*	1	3,710,795	01/1973	Higuchi et al	128/260
	*	2	5,294,715	03/1994	Papadopoulou-Rosenzweig et al:	546/106
	*	3	5,567,317	10/1996	Kauvar	210/635
	*	4	5,587,293	12/1996	Kauvar et al.	435/7.21
FOREIGN PATENT DOCUMENTS						
† EX'R INITIAL	*	REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)
	*	5	1 - 221364	09/1989	Japan	English abstract only
	*	6	0 446 604 A2	09/1991	EP	
	*	7	95/02397	01/1995	PCT	
	*	8	96/39818	12/1996	PCT	
	*	9	44 44 045	6/1996	DE	equivalent to #11
	*	10	2,164,766	6/1996	CA	
	*	11	97/27179	07/1997	PCT	
	*	12	98/54148	12/1998	PCT	
	*	13	99/58126	11/1999	PCT	
	*	14	99/64054	12/1999	PCT	
	*	15	00/32175	06/2000	PCT	
	*	16	00/32175	06/2000	PCT	
OTHER DOCUMENTS						
† EX'R INITIAL	*	REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)			
	*	17	Houghton, "Apoptosis and drug response", <i>Current Opinion in Oncology</i> , 1999, 11:475-481.			
	*	18	Siegel et al., "The Role of Fas and related death receptors in autoimmune and other disease states", <i>J Allergy Clin Immunol</i> , vol. 102, no. 5, part 1, May 1999.			
EXAMINER'S SIGNATURE				DATE CONSIDERED		
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. <i>Include copy of this form in next communication to applicant.</i>						
* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).						

